reports
Advaxis Reports Fiscal Year 2021 Financial Results and Provides a Busi...
Advaxis Reports Fiscal Year 2021 Financial Results and Provides a Business Update MONMOUTH JUNCTION, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announces its financial results for the fiscal year ended October 31, 2021 and provides a business update. Fiscal Year 2021 and Recent Key Accomplishments: Presented updated clinical data from ongoing Phase 1/2 Trial of ADXS-503 in NSCLC In Part B combination arm a second partial response...
Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Prefer...
Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement MONMOUTH JUNCTION, N.J., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company entered into an agreement with certain institutional investors for the private placement of 1,000,000 shares of Series D convertible redeemable preferred stock. The shares to be sold will have an aggregate stated value of $5,000,000. Each share of the...
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of...
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones Updated data show a second partial response in Part B Overall response rate of 15.4% and disease control rate of 46% in Part B with durable clinical benefit in patients with prior disease progression Preliminary data show disease control rate of 67% in first 3 patients in Part C, with ADXS-503 being dosed in combination with pembrolizumab in first line MONMOUTH JUNCTION, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnol...
Advaxis Announces Acceptance for Trading on the OTCQX
Advaxis Announces Acceptance for Trading on the OTCQX MONMOUTH JUNCTION, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company has satisfied the requirements for trading of the Company’s common stock on the OTCQX® Best Market (“OTCQX”) and will begin trading on OTCQX at the open of the market on December 23, 2021 under the symbol ADXS. The Company previously traded on Nasdaq. OTCQX is the top tier of three markets organized by ...
Advaxis to Continue to Explore Additional Options to Maximize Stockhol...
Advaxis to Continue to Explore Additional Options to Maximize Stockholder Value Stockholders approved Proposal 1 in support of Biosight merger Proposal 2 reverse stock split, a condition for completing the merger of Advaxis and Biosight, was not approved MONMOUTH JUNCTION, N.J., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that following the conclusion of its second reconvened special meeting of stockholders on December 16, 20...
Advaxis Issues Letter to Stockholders Regarding Recent Special Meeting...
Advaxis Issues Letter to Stockholders Regarding Recent Special Meeting Results Stockholders passed Proposals 1 (the Merger) and 4 (Executive Compensation) Advaxis urges stockholders to vote “FOR” Proposal 2 at the upcoming special meeting in order to best position the company to build long term stockholder value MONMOUTH JUNCTION, N.J., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today issued the following statement to stockholders: Dear Fel...
Advaxis Issues Letter and Second Video Message to Stockholders Regardi...
Advaxis Issues Letter and Second Video Message to Stockholders Regarding Upcoming Special Meeting Company releases video message highlighting the need for all proposals to pass in order to consummate the proposed Biosight transaction Advaxis urges stockholders to vote “FOR” all of the proposals at the special meeting in order to best position the company to build long term stockholder value MONMOUTH JUNCTION, N.J., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy produ...
Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to Comp...
Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to Complete Merger Transaction with Biosight, Ltd. and Satisfy Initial Listing Requirements MONMOUTH JUNCTION, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (“Advaxis” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products, announced that it has received a letter from the Nasdaq Hearings Panel (the “Panel”) providing Advaxis an extension through December 20, 2021, to complete its business combination wit...
Advaxis, Inc. Issues Letter to Stockholders
Advaxis, Inc. Issues Letter to Stockholders Advaxis urges stockholders to carefully evaluate the potential outcomes of the vote on the proposed merger with Biosight and vote FOR all proposals MONMOUTH JUNCTION, N.J., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today issued the following statement to stockholders: Dear Fellow Advaxis Stockholders: We have prepared this summary to highlight the starkly different scenarios Advaxis’ stockholder...
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recom...
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Advaxis Stockholders Vote “FOR” Proposed Merger with Biosight Advaxis urges stockholders to vote “FOR” the merger with Biosight and all proposals MONMOUTH JUNCTION, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that leading independent proxy advisory firm, Glass Lewis & Co. (Glass Lewis), joins Institutional Shareholder Services (ISS) in recommending that Ad...
Advaxis Issues Letter and Video Message to Stockholders Regarding Upco...
Advaxis Issues Letter and Video Message to Stockholders Regarding Upcoming Special Meeting Company releases video message highlighting strategic rationale and benefits of proposed Biosight transaction for Advaxis stockholders Advaxis urges stockholders to vote “FOR” all of the proposals at the special meeting in order to best position the company to build long term stockholder value MONMOUTH JUNCTION, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, tod...
Leading Independent Proxy Advisory Firm ISS Recommends Advaxis Stockho...
Leading Independent Proxy Advisory Firm ISS Recommends Advaxis Stockholders Vote “FOR” the Merger with Biosight MONMOUTH JUNCTION, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced that leading proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) issued a report on November 1, 2021, recommending that Advaxis stockholders vote “FOR” the merger of the Company with Biosight and recommends voting “FOR” all proposals, at the Compan...
Advaxis Reports 3rd Quarter Ended July 31, 2021 Financial Results and ...
Advaxis Reports 3rd Quarter Ended July 31, 2021 Financial Results and Provides a Business Update Entered definitive merger agreement with Biosight Ltd. to advance pipeline of clinical-stage oncology programs for solid tumors and hematological malignancies Initiated Phase 1 clinical trial of ADXS-504 for the treatment of early prostate cancer ADXS-503 Phase 1/2 data presented at ASCO demonstrate disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on KEYTRUDA® MONMOUTH JUNCTION, N.J., Sept. 10, 2021 (GLOBE NEWSWIRE) -- A...
Nasdaq Grants Advaxis, Inc. an Extension to November 22, 2021, to Rega...
Nasdaq Grants Advaxis, Inc. an Extension to November 22, 2021, to Regain Compliance with the $1.00 Minimum Bid Price Rule and Complete Merger Transaction with Biosight, Ltd. MONMOUTH JUNCTION, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (“Advaxis” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products, announced that it has received a letter indicating that following the Company’s hearing before the Nasdaq Hearings Panel (the “Panel”), the Panel determined to gra...
Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504 for...
Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer Study in biochemically recurrent prostate cancer expands off-the-shelf ADXS-HOT program to second indication MONMOUTH JUNCTION, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the initiation of its Phase 1 clinical study evaluating ADXS-504 in patients with biochemically recurrent prostate cancer. The study, being conducted at C...
Advaxis to Present at the Non-Small Cell Lung Cancer Drug Development ...
Advaxis to Present at the Non-Small Cell Lung Cancer Drug Development Summit PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Andres Gutierrez, M.D., Executive Vice President and Chief Medical Officer of Advaxis, will present data from Part B of the Company’s Phase 1/2 study of ADXS-503 in combination with Pembrolizumab in patients with metastatic squamous or non-squamous non-small cell lung cancer at the virtual Non-Small ...
Advaxis and Biosight Announce Entry into Definitive Merger Agreement
Advaxis and Biosight Announce Entry into Definitive Merger Agreement – Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) – Combined Company Will be Well-Funded with Cash Position of approx.$50 Million Expected at Closing – Multiple Clinical and Regulatory Pipeline Milestones Planned for Combined Company Over the Next 12-18 Months – Companies to Host Joint Conference Call on Tuesday, July 6, 2021 at 8:30 am EDT MONMOUTH...
Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results ...
Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results and Provides a Business Update ADXS-503 Phase 1/2 trial data presented at ASCO demonstrate disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on KEYTRUDA® Expansion of off-the-shelf ADXS-HOT program with planned Phase 1 study in early prostate cancer with biochemical recurrence Cash runway anticipated into fiscal 3rd quarter of 2023 PRINCETON, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology compa...
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of...
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting Updated data show disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on pembrolizumab Translational data support potential of ADXS-503 to restore and/or enhance sensitivity to checkpoint inhibitors PRINCETON, N.J., May 19, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commerciali...
Advaxis to Present at the American Society of Clinical Oncology (ASCO)...
Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting PRINCETON, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that will present data from Part B of the Phase 1 study of ADXS-503 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually, on June 4-8, 2021. Presentation Details: Title: A phase 1 study of an off-the-shelf, multi-neoanti...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.